The Swiss pharmaceutical company, Roche is on the verge of a multibillion-dollar acquisition in the US. The Wall Street Journal reported on Saturday citing familiar with the matter people, that Roche was interested in Spark Therapeutics.
The group intends to place for the biotech company for nearly five billion dollars on the table. Sparks market review fraud to trade the end on Friday, however, only just under two billion dollars.
According to the newspaper, there is at least one other unknown bidder for Spark. Neither Roche nor Spark wanted to Express. Already on Saturday there had been in Switzerland, too, occasionally, rumors about the transaction.
The acquisition could be announced on Monday or earlier. However, it is also possible that the negotiations failed and no transaction shall be concluded. The Biotech company specializes in the development of gene therapies. (chk/sda)
Created: 24.02.2019, 05:42 PM
